(Reuters) - Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the ...
The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.